Anzeige
Mehr »
Login
Donnerstag, 03.10.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Citibank sagt $3.000 Gold voraus: Lernen Sie das Unternehmen kennen, das sich seit Jahren darauf vorbereitet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
660 Leser
Artikel bewerten:
(2)

Royal Philips: Intuitive, integrated and efficient - world premiere of Philips' next-generation Azurion image-guided therapy platform


September 1, 2020

  • New level of integration across imaging, physiology, hemodynamic and informatics applications
  • SmartCT guides acquisition of 3D CT-like images and provides visualization and measurement tools
  • Increased efficiency and flexibility with tableside access to more modalities and intuitive control of the gantry

Amsterdam, the Netherlands -Royal Philipsimage-guided therapy platform, marking an important step forward in optimizing clinical and operational lab performance and expanding the role of image-guided interventions in the treatment of patients. Intuitive, integrated and efficient, the next-generation Azurion advances the capabilities of the platform to further improve the quality and efficiency of interventional procedures. The Azurion platform has already achieved rapid global adoption and has been used in well over two million procedures [1] worldwide since its introduction three years ago.

In the past few decades, clinical practices around the world have evolved to successfully treat more patients and perform more complex procedures in interventional labs. However, with more staff and technologies involved during these procedures, interventional lab environments can become crowded and cluttered. In order to enhance clinician focus and control during procedures, Philips has integrated all the essential lab systems and tools into this new version of the Azurion platform, making it an important step forward in lab integration.

An industry-first, the Philips Azurion image-guided therapy platform now integrates control of imaging, physiology, hemodynamic and informatics applications, as well as intuitive control of the gantry, at the tableside, allowing clinicians to control all compatible applications from a single touch screen while performing procedures. This can eliminate the need for clinicians to leave the sterile field and step into an adjacent control room, as well as supporting faster and better informed decision making.

Simplifying 3D imaging during interventional procedures
With this next-generation Azurion platform, Philips is also introducing a new 3D imaging solution called SmartCT [2]. With SmartCT, users are guided through the image acquisition and can review and interact with the acquired CT-like 3D images on the tableside touch screen module using 3D visualization and measurement tools. These tools have been designed to support procedures in a range of clinical domains, including neurology, oncology, and cardiovascular procedures. The use of 3D imaging such as 3D RA or Cone Beam CT during interventional procedures has been shown to improve outcomes [3] and reduce radiation dose for both staff and patients [4].

"Our aim as an innovation company and global market leader in image-guided therapy is to push the boundaries and set new industry standards for delivering an outstanding experience for clinicians, helping them to deliver superior care to every patient," said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. "This next-generation Azurion makes routine cardiovascular procedures more efficient and supports the development of new minimally-invasive techniques to treat complex diseases such as stroke, lung cancer and spine disorders."

"The integrated platform enables us to efficiently carry out complex interventions at any time using a wide range of functions such as IVUS and iFR co-registration," said Dr. med. Alexander Becker, head of the cardiac catheter laboratory at the Robert Bosch Hospital in Stuttgart, Germany, and one of the first hospitals to experience the new platform. "The use of the control panel by the examiner is intuitive, combining different sources of information to make patient evaluation much easier and faster."

Seamless control and workflow during procedures
With the new Azurion platform, clinicians can easily switch between imaging, physiology, hemodynamic and informatics applications, including SmartCT and IntraSight- a comprehensive suite of clinically proven iFR, FFR, IVUS and co-registration modalities. Fully automatic position control enables clinicians to intuitively control the position of the gantry and table, as well as choosing from a wide range of stored parameters. The new Azurion also includes advanced cybersecurity features, new high-definition image display capabilities, and advanced remote and proactive services. The platform is available in three versions: complementing the Azurion 3 and 7 variants, Philips now also offers the Azurion 5 to facilitate even more tailored solutions to address specific customer needs. For more information visit www.philips.com/azurion.

[1] Based on Philips' internal case and procedure data.
[2] SmartCT is 510(k) pending and not available for sale in the USA.
[3] Miyayama et al., 'Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma =6 cm with or without intraprocedural monitoring of the embolized area using cone beam computed tomography', CVIR 2014.
[4] Schott et al., 'Radiation dose in prostatic artery embolization using Cone Beam CT and 3D roadmap software, JVIR 2019.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com

Twitter: mark_groves

Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com

Twitter: FC_Feer

About Royal Philips

Royal Philips.

Attachments

  • Azurion image-guided therapy (https://ml-eu.globenewswire.com/Resource/Download/a7803d27-4b66-474e-94af-fd010898a0cc)
  • Azurion IntraSight tableside monitor (https://ml-eu.globenewswire.com/Resource/Download/31c167ee-43b4-48bd-b131-a4f097656f82)
  • Azurion SmartCT tableside monitor (https://ml-eu.globenewswire.com/Resource/Download/63bb1d11-15d5-4bcf-972c-6a22186aec7a)
© 2020 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.